Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/29/2024 | $200.00 → $125.00 | Outperform | Oppenheimer |
| 10/29/2024 | $208.00 → $109.00 | Buy | Needham |
| 9/24/2024 | $200.00 | Outperform | Robert W. Baird |
| 8/21/2024 | $208.00 | Buy | Needham |
| 6/6/2024 | $161.00 | Overweight | Cantor Fitzgerald |
| 6/4/2024 | $151.00 | Overweight | Stephens |
| 3/28/2024 | $95.00 | Overweight | Piper Sandler |
| 7/19/2023 | Outperform | Robert W. Baird |
Oppenheimer reiterated coverage of TransMedics Group with a rating of Outperform and set a new price target of $125.00 from $200.00 previously
Needham reiterated coverage of TransMedics Group with a rating of Buy and set a new price target of $109.00 from $208.00 previously
Robert W. Baird initiated coverage of TransMedics Group with a rating of Outperform and set a new price target of $200.00
144 - TransMedics Group, Inc. (0001756262) (Subject)
10-Q - TransMedics Group, Inc. (0001756262) (Filer)
8-K - TransMedics Group, Inc. (0001756262) (Filer)
4 - TransMedics Group, Inc. (0001756262) (Issuer)
4 - TransMedics Group, Inc. (0001756262) (Issuer)
4 - TransMedics Group, Inc. (0001756262) (Issuer)
ANDOVER, Mass., Oct. 29, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on October 23, 2024, TransMedics granted non-qualified stock options to purchase an aggregate of 2,969 shares of its common stock and an aggregate of 1,937 restricted stock units to 6 employees, each as a material inducement for each employee's entry into employment with TransMedics. The grants were approved by the Compensation Committee of the TransMedics Board of Directors and were granted in accordance with Nasdaq Listing Rule 5635(c)(4
ANDOVER, Mass., Oct. 28, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended September 30, 2024. Recent Highlights Total revenue of $108.8 million in the third quarter of 2024, a 64% increase compared to the third quarter of 2023Generated net income of $4.2 million or $0.12 per diluted share in the third quarter of 2024Owned 18 total aircraft as of September 30, 2024
ANDOVER, Mass., Oct. 15, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the third quarter 2024 after market close on Monday, October 28, 2024. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT. Investors interested in listening to the conference call may do so by dialing (844) 481-2832 for domes
SC 13G/A - TransMedics Group, Inc. (0001756262) (Subject)
SC 13G/A - TransMedics Group, Inc. (0001756262) (Subject)
SC 13G/A - TransMedics Group, Inc. (0001756262) (Subject)
NEW YORK, Sept. 26, 2024 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 and S&P MidCap 400: S&P SmallCap 600 constituent The Ensign Group Inc. (NASD: ENSG) will replace Southwestern Energy Co. (NYSE:SWN) in the S&P MidCap 400 and TransMedics Group, Inc. (NASD: TMDX) will replace The Ensign Group in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, October 1. S&P MidCap 400 constituent Chesapeake Energy Corp. (NASD: CHK) is acquiring Southwestern Energy in a deal expected to be completed October 1.Curbline Properties Corp. (NYSE:CURB) will be added to the S&P SmallCap 600 effective prior to the open of trading on Tuesda
ANDOVER, Mass., July 26, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today the appointment of Anil Ranganath as Senior Vice President, General Counsel and Corporate Secretary. "We are excited to welcome Anil to the TransMedics leadership team," said Waleed Hassanein, MD, President and Chief Executive Officer. "Anil brings a wealth of healthcare industry experience, and his knowledge and counsel will be
ANDOVER, Mass., Feb. 2, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today the appointment of Nick Corcoran as Senior Vice President of Supply Chain and Operations, effective immediately. "Nick has extensive end-to-end supply chain and operations experience making him the perfect fit for TransMedics as we expand our operations to meet the growing global demand for OCS products and service," said Waleed H
TransMedics Gr (NASDAQ:TMDX) has outperformed the market over the past 5 years by 30.55% on an annualized basis producing an average annual return of 43.06%. Currently, TransMedics Gr has a market capitalization of $5.09 billion. Buying $1000 In TMDX: If an investor had bought $1000 of TMDX stock 5 years ago, it would be worth $5,892.80 today based on a price of $154.60 for TMDX at the time of writing. TransMedics Gr's Performance Over Last 5 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated con
TransMedics Gr (NASDAQ:TMDX) has outperformed the market over the past 5 years by 27.68% on an annualized basis producing an average annual return of 41.28%. Currently, TransMedics Gr has a market capitalization of $4.75 billion. Buying $100 In TMDX: If an investor had bought $100 of TMDX stock 5 years ago, it would be worth $587.32 today based on a price of $144.09 for TMDX at the time of writing. TransMedics Gr's Performance Over Last 5 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content
Morgan Stanley analyst Patrick Wood maintains TransMedics Gr (NASDAQ:TMDX) with a Equal-Weight and raises the price target from $104 to $145.
ANDOVER, Mass., Oct. 28, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended September 30, 2024. Recent Highlights Total revenue of $108.8 million in the third quarter of 2024, a 64% increase compared to the third quarter of 2023Generated net income of $4.2 million or $0.12 per diluted share in the third quarter of 2024Owned 18 total aircraft as of September 30, 2024
ANDOVER, Mass., Oct. 15, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the third quarter 2024 after market close on Monday, October 28, 2024. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT. Investors interested in listening to the conference call may do so by dialing (844) 481-2832 for domes
ANDOVER, Mass., July 31, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended June 30, 2024. Recent Highlights Total revenue of $114.3 million in the second quarter of 2024, a 118% increase compared to the second quarter of 2023Generated net income of $12.2 million or $0.35 per diluted share in the second quarter of 2024Owned 15 total aircraft as of June 30, 2024Purc